Synopsys (SNPS) CRO Awarded Restricted Stock Units
SYNOPSYS INC
Subscribe to track SNPS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Synopsys (SNPS) CRO Awarded Restricted Stock Units
Company: SYNOPSYS INC (SNPS) Form: 4 | Filed: 2025-12-15 Significance: Low
Insider: Ellow Michael Title: Chief Revenue Officer | Relationship: Officer
Transaction: • Type: Grant • Shares: 24,286 (Restricted Stock Units) • Price: $0.00 • Value: $0 • Owned After: 24,286 units
Key Insight: This is a routine equity grant as part of executive compensation. The shares represent 0.013% of total outstanding shares, a minimal dilution impact.
Market Context: Such grants are a standard practice for large-cap tech companies like Synopsys to retain and incentivize key executives.
Comprehensive Analysis
SEC Filing Analysis: SYNOPSYS INC (SNPS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: The Chief Revenue Officer received a routine grant of 24,286 Restricted Stock Units (RSUs) as part of their compensation package.
- Market Impact: Neutral. This is a non-market transaction and a standard form of executive compensation with minimal immediate market impact.
Company Information
| Field | Value |
|---|---|
| Company | SYNOPSYS INC |
| Ticker Symbol | SNPS |
| CIK | 0000883241 |
| Industry | SERVICES-PREPACKAGED SOFTWARE |
Insider Information
| Field | Value |
|---|---|
| Name | Ellow Michael |
| CIK | 0001615442 |
| Title/Position | Chief Revenue Officer |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-12-12 |
| Transaction Code | A (Grant) |
| Security Type | Restricted Stock Units |
| Shares Involved | 24,286 |
| Price Per Share | $0.00 |
| Total Value | $0 |
| Shares Owned After | 24,286 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0 |
| % of Market Cap | 0.0% |
| Shares Transacted | 24,286 |
| % of Shares Outstanding | 0.013% |
| Post-Transaction Ownership | 24,286 units (0.013% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: Synopsys is a large-cap company with a market capitalization of $72.41 billion. This equity grant is immaterial in value relative to the company's size.
- Ownership Concentration: This grant establishes the insider's initial reported holdings in this security type, representing a very small fraction (0.013%) of total shares outstanding.
- Dilution Impact: The issuance of 24,286 shares upon vesting will have a negligible dilutive effect on existing shareholders, increasing the share count by only 0.013%.
- Transaction Significance: The transaction is classified as low significance because it is a non-cash grant and represents a tiny fraction of the company's shares outstanding and market capitalization.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Equity grants are a standard and expected part of executive compensation plans, particularly in the technology sector. They do not reflect an insider's market sentiment in the same way an open-market purchase or sale does.
Volume & Sentiment
- Expected Volume Impact: None. This is not an open-market transaction and will not directly affect trading volume.
- Sentiment Indicator: Neutral. The market generally views routine RSU grants as a standard cost of doing business to retain talent.
Additional Context
Transaction Notes
- Vesting Schedule: According to footnote 2, one-sixth (1/6) of the units will vest on June 15, 2026, followed by five equal semi-annual installments, contingent on the insider's continued service. This long vesting schedule aligns the executive's interests with long-term shareholder value.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
